The focus on the first 100 days of the Obama presidency rightly counted his many accomplishments. But perhaps even more profound is his vision: the promise of breakthroughs in science, technology and medicine.
The United States must focus on the promises on the horizon — discoveries that will find cures and save and improve lives far beyond our borders. Our role as the world's leader in medical innovation cannot be taken for granted. The truth is that we are losing our edge — even as other countries are joining the race.
Asian countries now outpace the U.S. in research and development spending. An increased demand for skilled science and engineering students in Europe, China and India has resulted in a reverse brain-drain, with too many of our skilled immigrant workers leaving the U.S. to work abroad.
Medical innovation and discovery have traditionally been a cornerstone of a flourishing America. Besides keeping us healthy, our healthcare industry provides good jobs: approximately 14 million jobs today and an expected 3 million new jobs between now and 2016 — more than any other industry.
Still, there remains an understanding gap in the vital role that medical innovation plays in our economy, as well as our global competitiveness.
President Obama gets it. In his first 100 days in office, the president has called for a reinvigorated effort to cure cancer, opened new doors for discovery through stem cell research, and committed to improving math and science education.
He has also convened an esteemed committee of the very top thinkers on the President's Council of Advisors on Science and Technology. Perhaps most indicative of his strong commitment to restore U.S. leadership in the life sciences and technology, he has promised to devote more than 3 percent of the U.S. gross domestic product —amounting to hundreds of billions of dollars per year — on research and development.
These historic investments will go a long way toward ensuring our economic recovery. Curing cancer — and fixing our economy — can be done. But it will require new and better medical treatments, as well as smarter policy.
To continue to achieve medical triumphs and safeguard the president's investments, we need policies that support research, discovery and development for new groundbreaking therapies. In President Obama's words, we must “once again put science at the top” in our budgets and in our legislation. That includes creating incentives to encourage collaborative research across the public and private sectors — something that is no longer a given in this economy.
National policies must be modernized to improve math and science education, make regulatory processes more efficient, create incentives for investment in medical discovery and make more-sensible immigration rules for talented students.
We have a president with the vision to see America's brightest future and the wisdom to lead us on the right path. It takes courage and discipline to invest intelligently when the economy is in recession. But failure would be far more expensive. We must invest in the technologies of science, research and education. President Obama has pointed to the horizon. It is now up to this Congress to follow his lead by enacting the smart policies that will be critical to the success of American medical innovation.
Gephardt, former House Democratic leader (Mo.), is president and CEO of Gephardt Government Affairs and president of the Coalition for American Medical Innovation.
Breaux and Gephardt. Gerard and Maloney. Berman and Podesta. According to First Street, these were among the most powerful lobbyists in Washington this year.
...Tom O'Donnell, Gephardt Government Affairs Group. O'Donnell and his former Capitol Hill boss, ex-House Democratic Leader Richard Gephardt (Mo.), have done well since joining forces...
Read More
Gephardt's former chief of staff Tom O'Donnell talks to National Journal about post-debt ceiling debate prospects for bipartisanship.
Read More
Video: How Will FAA Crisis Affect You?
Watch Video
Debt-limit votes have been called the "burden of the majority" — an unpleasant chore that needed to be done by whichever party happens to be in power.
Read More
Christina Hamilton, Former Chief of Staff to House Appropriations Committee Chairman Dave Obey, will join the firm. As a Senior Vice President with the firm, Christina will support the firm’s health, energy, transportation, trade and appropriations clients.
Watch Video
Life on the outside after more than 41 years in Congress hasn’t been much different for former House Appropriations Chairman David Obey, D-Wis. — or so it seems.
Read More
Dick Gephardt participated in Vice President Joe Biden, Dr. Jill Biden and Secretary of State Hillary Clinton’s welcoming lunch honoring Her Excellency Dr. Angela Merkel, Chancellor of the Federal Republic of Germany.
Watch Video
Gephardt Government Affairs President & CEO Dick Gephardt announced that Former House Appropriations Committee Chairman Dave Obey will join the firm.
Read More
"If there was a tough leadership assignment in the country right now, it would be this job — at the top of everybody's list," says former House majority leader Richard Gephardt, who first recommended Panetta to President Clinton as his budget director. Panetta later became White House chief of staff.
Read More
Dick comments on the "Gephardt rule" as the debt ceiling debate heats up.
Read More